

GenCore version 5.1.6  
Copyright (c) 1993 - 2003. Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 29, 2003, 15:08:32 ; Search time 70 Seconds  
(Without alignments)  
154.190 Million cell updates/sec

Title: US-09-924-102-2  
Perfect score: 418  
Sequence: 1 MLSTHFLFIYLFPLSYSL.....RMGQGGRGSTADTGWFLS 81

Scoring table: BLASTSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A\_Geneseq\_101002:\*

- 1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:\*
- 2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:\*
- 3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:\*
- 4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:\*
- 5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:\*
- 6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:\*
- 7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:\*
- 8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:\*
- 9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:\*
- 10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:\*
- 11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:\*
- 12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:\*
- 13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:\*
- 14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:\*
- 15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:\*
- 16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:\*
- 17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:\*
- 18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:\*
- 19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:\*
- 20: /SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:\*
- 21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:\*
- 22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:\*
- 23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	418	100.0	81	23	AAE19840	Human homologue of
2	90	21.5	20	23	AAE19842	Human hkrp derived
3	81	19.4	77	21	AAE02365	Human secreted pro
4	78.5	18.8	61	22	AAE88846	Human immune/haema
5	78.5	18.8	115	22	ABG10494	Novel human diagno
6	78	18.7	281	22	AAU87124	Novel central nerv
7	77	18.4	77	22	AAO06132	Human polypeptide
8	77	18.4	120	20	AA774184	Human prostate tum
9	75	17.9	79	22	AAO13129	Human polypeptide
10	75	17.9	182	22	ABG26501	Novel human diagno

11	74.5	17.8	61	22	AAE91214	Human immune/haema
12	74.5	17.8	99	22	AAO07806	Human polypeptide
13	73.5	17.6	924	22	ABG39845	Novel human diagno
14	73	17.5	59	22	AAE86657	Human immune/haema
15	73	17.5	482	22	AAE84911	Shrimp white spot
16	72	17.2	102	22	AAE25887	Human protein sequ
17	71	17.0	163	22	AAE75462	Human colon cancer
18	71	17.0	181	22	AAU29487	Human G protein co
19	71	17.0	181	22	ABG60775	Novel G protein co
20	70.5	16.9	39	22	AAE85158	Human immune/haema
21	70.5	16.9	87	22	ABG19765	Novel human diagno
22	70.5	16.9	1049	22	ABE60701	Drosophila melanog
23	69	16.5	655	22	ABE61625	Drosophila melanog
24	68.5	16.4	156	22	AAU11343	Novel human secret
25	68	16.3	72	22	AAO07607	Human polypeptide
26	68	16.3	462	22	AAU35372	Human polypeptide
27	67.5	16.1	100	23	ABE04598	Human centrosomal
28	67.5	16.1	734	22	ABG18054	Novel human diagno
29	67	16.0	808	22	ABE70322	Drosophila melanog
30	66.5	15.9	115	22	AAO04729	Human polypeptide
31	66.5	15.9	135	22	AAO04856	Human polypeptide
32	66	15.8	35	22	AAE83720	Human immune/haema
33	66	15.8	118	20	AAE59777	Human normal ovar
34	65.5	15.7	1783	22	ABE63930	Drosophila melanog
35	65	15.6	65	15	AAE55789	Cell death reaper
36	65	15.6	65	22	ABE60552	Drosophila melanog
37	65	15.6	65	22	AAE65246	D melanogaster apo
38	65	15.6	65	23	AAE19839	Drosophila melanog
39	65	15.6	138	21	AAE43352	Human ORFX protein
40	65	15.6	138	23	ABE08478	Human prostate-cdn
41	65	15.6	222	22	AAU69783	Human prostate-cdn
42	65	15.6	222	22	AAO01138	Human prostate-spe
43	65	15.6	222	23	AAE99023	Human prostate-spe
44	65	15.6	222	23	ABE95243	Human prostate-spe
45	65	15.6	287	22	ABG15575	Novel human diagno

#### ALIGNMENTS

RESULT 1	AAE19840	standard; Protein; 81 AA.
ID	AAE19840	
AC	AAE19840;	
XX	18-JUN-2002	(first entry)
DE	Human homologue of Drosophila melanogaster reaper protein (hkrp).	
KW	Human; reaper protein; Rpr; detection; purification; screening;	
KW	therapy; tumour; cytostatic; protein.	
XX		
OS	Homo sapiens.	
XX		
FT	Key	Location/Qualifiers
FT	Region	5..17
FT	Region	/label= Alpha_helix
FT	Region	23..42
FT	Region	/label= Alpha_helix
FT	Misc-difference	38
FT	/note= "Encoded by AAA"	43..55
FT	Region	/label= Alpha_helix
XX		
XX	WO200212540-A2.	
XX		
XX	14-FEB-2002.	
XX		
XX	08-AUG-2001; 2001WO-US24765.	
XX		
XX	08-AUG-2000; 2000US-223699P.	
XX		

```

PA (UYDU-) UNITV DUKE.
XX
XX Kornbluth SA, Holley C;
XX
XX WPI; 2002-241769/29.
XX
XX N-PSDB; AAD31598.
XX
XX New human homologue of Drosophila melanogaster reaper protein (hrpr),
XX useful for generating antibodies and for screening compounds, which can
XX inhibit or enhance hrpr activity
XX
XX Claim 1; Fig 1; 45pp; English.
XX
XX The invention relates to human homologue of Drosophila melanogaster
XX reaper protein (hrpr) and its corresponding nucleic acid. The hrpr
XX polypeptides are useful for generating antibodies, which can be used
XX in detection or purification protocols designed to detect or purify
XX the polypeptide to which the antibody is directed. These sequences
XX are also used for screening compounds, which can enhance or inhibit
XX hrpr and for treating tumours. The hrpr polynucleotides are useful
XX as a probe or primer. The present sequence is human homologue of
XX Drosophila melanogaster reaper protein (hrpr).
XX
XX Sequence 81 AA;
XX
XX Query Match 100.0%; Score 418; DB 23; Length 81;
XX Best Local Similarity 100.0%; Pred. No. 9.1e-42;
XX Matches 81; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 MLSTHLFIYLFYFYFYSIGDRAFLCLRTKQKQKROEOTLRQSEVLFPSSETLRKTKGG 60
XX |||||
XX 1 MLSTHLFIYLFYFYSIGDRAFLCLRTKQKQKROEOTLRQSEVLFPSSETLRKTKGG 60
XX
XX Db 61 RRMGGGGRGRTADTGGMFLS 81
XX |||||
XX 61 RRMGGGGRGRTADTGGMFLS 81
XX
XX Db 61 RRMGGGGRGRTADTGGMFLS 81
XX
XX RESULT 2
XX AAE19842
XX ID AAE19842 standard; peptide; 20 AA.
XX
XX AAE19842;
XX
XX 18-JUN-2002 (first entry)
XX
XX Human hrpr derived peptide.
XX
XX Human reaper protein; Rpr; detection; purification; screening;
XX therapy; tumour; cytostatic.
XX
XX Homo sapiens.
XX
XX WO200212540-A2.
XX
XX 14-FEB-2002.
XX
XX 08-AUG-2001; 2001WO-US24765.
XX
XX 08-AUG-2000; 2000US-223699P.
XX
XX (UYDU-) UNITV DUKE.
XX
XX Kornbluth SA, Holley C;
XX
XX WPI; 2002-241769/29.
XX
XX New human homologue of Drosophila melanogaster reaper protein (hrpr),
XX useful for generating antibodies and for screening compounds, which can
XX inhibit or enhance hrpr activity
XX
XX Example 1; Page 19; 45pp; English.
XX

```

```

CC The invention relates to human homologue of Drosophila melanogaster
CC reaper protein (hrpr) and its corresponding nucleic acid. The hrpr
CC polypeptides are useful for generating antibodies, which can be used
CC in detection or purification protocols designed to detect or purify
CC the polypeptide to which the antibody is directed. These sequences
CC are also used for screening compounds, which can enhance or inhibit
CC hrpr and for treating tumours. The hrpr polynucleotides are useful
CC as a probe or primer. The present sequence is human homologue of
CC Drosophila melanogaster reaper protein (hrpr) derived peptide.
CC
XX
XX Sequence 20 AA;
XX
XX Query Match 21.5%; Score 90; DB 23; Length 20;
XX Best Local Similarity 95.0%; Pred. No. 0.00092;
XX Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 36 KEQQLROSEVLFPSSETLRK 55
XX ||:|||||
XX 1 KEQQLROSEVLFPSSETLRK 20
XX
XX Db 1 KEQQLROSEVLFPSSETLRK 20
XX
XX RESULT 3
XX AAG02365
XX ID AAG02365 standard; Protein; 77 AA.
XX
XX AAG02365;
XX
XX 06-OCT-2000 (first entry)
XX
XX Human secreted protein, SEQ ID NO: 6446.
XX
XX Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
XX gene therapy; chromosome mapping.
XX
XX Homo sapiens.
XX
XX EP1033401-A2.
XX
XX 06-SEP-2000.
XX
XX 21-FEB-2000; 2000EP-0200610.
XX
XX 26-FEB-1999; 99US-0122487.
XX
XX (GEST ) GENSET.
XX
XX Dumas Milne Edwards J, Duclert A, Giordano J;
XX
XX WPI; 2000-500381/45.
XX
XX N-PSDB; AAC02371.
XX
XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for
XX obtaining cDNAs and genomic DNAs that correspond to 5' ESTs and for
XX diagnostic, forensic, gene therapy and chromosome mapping procedures -
XX Claim 13; SEQ ID 6446; 71pp + CD-ROM; English.
XX
XX The present sequence is a polypeptide encoded by one of a large number
XX of 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs
XX were prepared from total human RNAs or polyA+ RNAs derived from 30
XX different tissues. EST sequences usually correspond mainly to the 3'
XX untranslated region (UTR) of the mRNA because they are often obtained
XX from oligo-dT primed cDNA libraries. Such ESTs are not well suited for
XX isolating cDNA sequences derived from the 5' ends of mRNAs and even in
XX those cases where longer cDNA sequences have been obtained, the full 5'
XX UTR is rarely included. 5' ESTs are derived from mRNAs with intact 5'
XX ends and can therefore be used to obtain full length cDNAs and genomic
XX DNAs. 5' ESTs are also used in diagnostic, forensic, gene therapy and
XX chromosome mapping procedures. They are used to obtain upstream
XX regulatory sequences and to design expression and secretion vectors.
XX
XX Sequence 77 AA;
XX

```

us-09-924-102-2\_1.rag

PR	06-SEP-2000;	2000US-0230438
PR	08-SEP-2000;	2000US-0231242
PR	08-SEP-2000;	2000US-0231243

PR	08-SEP-2000;	2000US-0231413
PR	08-SEP-2000;	2000US-0231414
PR	08-SEP-2000;	2000US-0232080

PR	14-SEP-2000;	2000US-02323397
PR	14-SEP-2000;	2000US-02323398

PR 14-SEP-2000; 2000US-0232401

PR 14-SEP-2000; 2000US-0233064

PR 21-SEP-2000; 2000US-0234223

PR 25-SEP-2000; 2000US-0234997  
PR 25-SEP-2000; 2000US-0234998

PR 27-SEP-2000; 2000US-0235834.

PR 29-SEP-2000; 2000US-0236327

PR 29-SEP-2000; 2000US-0236368.

PR 29-SEP-2000; 2000US-0236370.

PR 02-OCT-2000; 2000US-0237037

PR 02-OCT-2000; 2000US-0237039.

PR 13-OCT-2000; 2000US-0239935.

PR 20-OCT-2000; 2000US-0240960.

PR 20-OCT-2000; 2000US-0241785.

PR 20-OCT-2000; 2000US-0241787.

PR 20-OCT-2000; 2000US-0241809.

PR 01-NOV-2000: 2000US-0244617.

PR	08-NOV-2000; 2000US-0246474.
PR	08-NOV-2000; 2000US-0246475.

PR	08-NOV-2000; 2000US-0246476.
PR	08-NOV-2000; 2000US-0246477.

PR	08-NOV-2000; 2000US-0246478.
PR	08-NOV-2000; 2000US-0246523.

PR	08-NOV-2000; 2000US-0246524.
PR	08-NOV-2000; 2000US-0246525.

PR	08-NOV-2000; 2000US-0246526.
PR	08-NOV-2000; 2000US-0246527.

PR	08-NOV-2000; 2000TS-0246528.
PR	08-NOV-2000; 2000TS-0246532.

PR	08-NOV-2000; 2000TS-0246609.
PR	08-NOV-2000; 2000TS-0246610.

PR	08-NOV-2000; 2000US-0246611.
PR	08-NOV-2000; 2000US-0246613

PR	17-NOV-2000; 2000US-0249207.
PR	17-NOV-2000; 2000TS-0249208.

PR 17-NOV-2000; 2000US-0249209.  
BP 17-NOV-2000; 2000US-0249210

PR	17-NOV-2000; 2000US-0249211.
PR	17-NOV-2000; 2000US-0249212.

PR 17-NOV-2000; 2000US-0249213.  
 PR 17-NOV-2000; 2000US-0249214

PR 17-NOV-2000; 2000US-0249215.  
 PR 17-NOV-2000; 2000US-0249215.

PR 17-NOV-2000; 2000US-0249217.

KV		Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW		food supplement; medical imaging; diagnostic; genetic disorder.
OS	Homo sapiens.	
PX	WO200175067-A2.	
PN		
PP	11-OCT-2001.	
XX		
XX	30-MAR-2001; 2001WO-US08631.	
PR	31-MAR-2000; 2000US-0540217.	
FR	23-AUG-2000; 2000US-0649167.	
PA	(HYSE-) HYSEQ INC.	
PL	Drimanac RT, Liu C, Tang YT;	
DR	WPI; 2001-639362/73.	
XX	N-PSDB; AAS74681.	
PT	New isolated polynucleotide and encoded polypeptides, useful in	
PT	diagnostics, forensics, gene mapping, identification of mutations	
PT	responsible for genetic disorders or other traits and to assess	
XX	biodiversity -	
PS	Claim 20; SEQ ID NO 40853; 103bp; English.	
CC	The invention relates to isolated polynucleotide (I) and	
CC	polypeptide (II) sequences. (I) is useful as hybridisation probes,	
CC	polymerase chain reaction (PCR) primers, oligomers, and for chromosome	
CC	and gene mapping, and in recombinant production of (II). The	
CC	polynucleotides are also used in diagnostics as expressed sequence tags	
CC	for identifying expressed genes. (II) is useful in gene therapy techniques	
CC	to restore normal activity of (II) or to treat disease states involving	
CC	(II). (II) is useful for generating antibodies against it, detecting or	
CC	quantitating a polypeptide in tissue, as molecular weight markers and as	
CC	a food supplement. (II) and its binding partners are useful in medical	
CC	imaging of sites expressing (II). (I) and (II) are useful for treating	
CC	disorders involving aberrant protein expression or biological activity.	
CC	The polypeptide and polynucleotide sequences have applications in	
CC	diagnostics, forensics, gene mapping, identification of mutations	
CC	responsible for genetic disorders or other traits to assess biodiversity	
CC	and to produce other types of data and products dependent on DNA and	
CC	amino acid sequences. ABG00010-ABG30377 represent novel human	
CC	diagnostic amino acid sequences of the invention.	
CC	Note: The sequence data for this patent did not appear in the printed	
CC	specification, but was obtained in electronic format directly from WIPO	
CC	at ftp.wipo.int/pub/published_pct_sequences.	
SQ	Sequence 115 AA:	
	Query Match 18.8%; Score 78.5; DB 22; Length 115;	
	Best Local Similarity 57.1%; Pred. No. 0.14;	
Matches	16; Conservative 7; Mismatches 2; Indels 3; Gaps 1	
QY	20 LGDRAALCLKRTKQQKEQILRQSEVL 47      :::    :   ::	
Db	65 LGDRAALCLKQQQKKQKKQKKQ---QQQLL 89	
RESULT 6		
ID	AAU87124 standard; Protein; 281 AA.	
XX	AAU87124;	
DT	05-JUN-2002 (first entry)	
XX		
XX	Novel central nervous system protein #34.	
KW	Central nervous system; CNS; autoimmune disease; rheumatoid arthritis;	
KW	hyperproliferative disorder; neoplasia; cardiovascular disorder;	

KW	cardiac arrest; cerebrovascular disorder; ischemia; anglogenesis;	PR	14-SEP-2000	2000US-02332401
KW	cardiac arrest; cerebrovascular disorder; ischemia; anglogenesis;	PR	14-SEP-2000	2000US-02330363
KW	acquired immunodeficiency virus; dysphagia; gastrointestinal disorder;	PR	14-SEP-2000	2000US-02330660
KW	adenocarcinoma; reproductive system disorder; testicular feminisation;	PR	14-SEP-2000	2000US-02330655
KW	adrenocortical disorder; diabetes; cancer; leukemia; neovascularization;	PR	21-SEP-2000	2000US-02344223
KW	respiratory disorder; renal disorder; kidney failure; blood disorder;	PR	21-SEP-2000	2000US-02344774
KW	myocardial infarction; wound healing; cell proliferation; skin aging;	PR	25-SEP-2000	2000US-02343597
KW	food additive; food preservative; gene therapy.	PR	25-SEP-2000	2000US-02343598
XX		PR	26-SEP-2000	2000US-02354844
XX	Homo sapiens.	PR	26-SEP-2000	2000US-02355834
XX		PR	27-SEP-2000	2000US-02358366
XX		PR	29-SEP-2000	2000US-02363277
XX		PR	29-SEP-2000	2000US-02363637
XX		PR	29-SEP-2000	2000US-02363688
XX		PR	29-SEP-2000	2000US-02363699
XX		PR	29-SEP-2000	2000US-02363700
XX		PR	29-SEP-2000	2000US-02363701
XX		PR	29-SEP-2000	2000US-02363702
XX		PR	29-SEP-2000	2000US-02363703
XX		PR	29-SEP-2000	2000US-02363704
XX		PR	29-SEP-2000	2000US-02363705
XX		PR	29-SEP-2000	2000US-02363706
XX		PR	29-SEP-2000	2000US-02363707
XX		PR	29-SEP-2000	2000US-02363708
XX		PR	29-SEP-2000	2000US-02363709
XX		PR	29-SEP-2000	2000US-02363710
XX		PR	29-SEP-2000	2000US-02363711
XX		PR	29-SEP-2000	2000US-02363712
XX		PR	29-SEP-2000	2000US-02363713
XX		PR	29-SEP-2000	2000US-02363714
XX		PR	29-SEP-2000	2000US-02363715
XX		PR	29-SEP-2000	2000US-02363716
XX		PR	29-SEP-2000	2000US-02363717
XX		PR	29-SEP-2000	2000US-02363718
XX		PR	29-SEP-2000	2000US-02363719
XX		PR	29-SEP-2000	2000US-02363720
XX		PR	29-SEP-2000	2000US-02363721
XX		PR	29-SEP-2000	2000US-02363722
XX		PR	29-SEP-2000	2000US-02363723
XX		PR	29-SEP-2000	2000US-02363724
XX		PR	29-SEP-2000	2000US-02363725
XX		PR	29-SEP-2000	2000US-02363726
XX		PR	29-SEP-2000	2000US-02363727
XX		PR	29-SEP-2000	2000US-02363728
XX		PR	29-SEP-2000	2000US-02363729
XX		PR	29-SEP-2000	2000US-02363730
XX		PR	29-SEP-2000	2000US-02363731
XX		PR	29-SEP-2000	2000US-02363732
XX		PR	29-SEP-2000	2000US-02363733
XX		PR	29-SEP-2000	2000US-02363734
XX		PR	29-SEP-2000	2000US-02363735
XX		PR	29-SEP-2000	2000US-02363736
XX		PR	29-SEP-2000	2000US-02363737
XX		PR	29-SEP-2000	2000US-02363738
XX		PR	29-SEP-2000	2000US-02363739
XX		PR	29-SEP-2000	2000US-02363740
XX		PR	29-SEP-2000	2000US-02363741
XX		PR	29-SEP-2000	2000US-02363742
XX		PR	29-SEP-2000	2000US-02363743
XX		PR	29-SEP-2000	2000US-02363744
XX		PR	29-SEP-2000	2000US-02363745
XX		PR	29-SEP-2000	2000US-02363746
XX		PR	29-SEP-2000	2000US-02363747
XX		PR	29-SEP-2000	2000US-02363748
XX		PR	29-SEP-2000	2000US-02363749
XX		PR	29-SEP-2000	2000US-02363750
XX		PR	29-SEP-2000	2000US-02363751
XX		PR	29-SEP-2000	2000US-02363752
XX		PR	29-SEP-2000	2000US-02363753
XX		PR	29-SEP-2000	2000US-02363754
XX		PR	29-SEP-2000	2000US-02363755
XX		PR	29-SEP-2000	2000US-02363756
XX		PR	29-SEP-2000	2000US-02363757
XX		PR	29-SEP-2000	2000US-02363758
XX		PR	29-SEP-2000	2000US-02363759



us-09-924-102-2\_1.rag

DR		WPI; 1999-621386/54.
DR	N-PSDB;	AAZ52980.
PT	New human nucleic acid sequences from pancreatic tumors, and related proteins -	
PR		
XX		
XX		
PS	Claim 23; Page 464; 502pp; German.	
XX		
CC	This invention describes novel polypeptides and their encoding nucleic acids derived from human pancreatic tumor tissue which have cytostatic activity. The sequences are also useful in producing pharmaceutical compositions for treatment of pancreatic tumors. AAY73814-Y74252	
CC	represent protein fragments encoded by the human pancreatic tumor CDNA library derived expressed sequence tag (EST) sequences represented in AA52858-453014.	
CC		
XX		
SQ	Sequence	120 AA;
	Query Match	18.4%; Score 77; DB 20; Length 120;
	Best Local Similarity	30.8%; Pred. No. 0.22;
	Matches	24; Conservative 7; Mismatches 23; Indels 24; Gaps 3;
QY	5 THLEFYLTFLVLSLGDRAHLCLRTKQQKKEQIILNQSEVLFRSFETLRKTGKKGRWG	64
Dd	2 TLTFEFFFFFELRSLG-----FIRSTVGLTFRSEAPPSHGVS-----G	38
QY	65 GGGRGCGTAD-TGGMFLS	81
	::  ::	
Dd	39 DSGRGGNPSEHPGCGVVS	56
RESULT 9		
AAOI3129		
ID	AAOI3129 standard; Protein; 79 AA.	
XX		
AC	AAOI3129;	
XX		
DT	06-NOV-2001 (first entry)	
XX		
DE	Human polypeptide SEQ ID NO 27021.	
XX		
KW	Human; cytokine; cell proliferation; cell differentiation; gene therapy;	
KW	vaccine; peptide therapy; stem cell growth factor; haematopoiesis;	
KW	tissue growth factor; immunomodulatory; cancer; leukaemia;	
KW	nervous system disorders; arthritis; inflammation.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200164835-A2.	
XX		
PD	07-SEP-2001.	
XX		
PF	26-FEB-2001; 2001WO-USO49927.	
XX		
PX	28-FEB-2000; 2000US-0515126.	
PR	18-MAY-2000; 2000US-0577409.	
XX		
PA	(HYSE-) HYSEQ INC.	
XX		
PI	Tang YT, Liu C, Drmanac RT;	
XX		
DR	WPI; 2001-514838/56.	
DR	N-PSDB; AAI93060.	
XX		
PT	Isolated nucleic acids and polypeptides, useful for preventing	
FT	diagnosing and treating e.g. leukaemia, inflammation and immune	
PP	disorders -	
XX		
XX		
PS	Claim 20; SEQ ID NO 27021; 1399pp + Sequence Listing; English.	
CC	The invention relates to human polynucleotides (AAI79941-AAI93841) and	
CC	the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to	
CC	cytokine, cell proliferation or cell differentiation or which may induce	

CC	production of other cytokines in other cell populations. The
CC	polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC	peptide therapeutics. The polypeptides have various cytokine-like activities,
CC	e.g. stem cell growth factor activity, haematopoiesis regulating
CC	activity, tissue growth factor activity, immunomodulatory activity and
CC	activin/inhibin activity and may be useful in the diagnosis and/or
CC	treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC	inflammation.
CC	Note: The sequence data for this patent did not form part of the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct_sequences.
XX	
SQ	Sequence      79 AA;
OY	
Db	Query Match                  17.9%; Score 75; DB 22; Length 79; Best Local Similarity    52.0%; Pred. No. 0.24; Matches    13; Conservative    8; Mismatches    4; Indels         0; Gaps         0;
	16 LSYSLGDRARLCRLKRTQQOKEQGI 40 - : : : : : : : : : : : : : : : : 42 LDFSIGKARLCLKKKKKKRKQRTL 66
RESULT 10	
ID	ABG26501 standard; Protein: 182 AA.
AC	ABG26501;
DT	18-FEB-2002 (first entry)
DE	Novel human diagnostic protein #26492.
KW	Human: chromosome mapping; gene mapping; gene therapy; forensic;
OS	food supplement; medical imaging; diagnostic; genetic disorder.
PN	Homo sapiens.
WO	WO200175067-A2.
PD	11-OCT-2001.
PR	30-MAR-2001; 2001WO-US08631.
PR	31-MAR-2000; 2000US-0540217.
PR	23-AUG-2000; 2000US-0649167.
PA	(HYSE-) HYSEQ INC.
PI	Drmnac RT, Liu C, Tang YT;
DR	WPI: 2001-639362/73. N-PSDB: AAS90688.
PT	New isolated polynucleotide and encoded polypeptides, useful in
PT	diagnostics, forensics, gene mapping, identification of mutations
PT	responsible for genetic disorders or other traits and to assess
PT	biodiversity -
PS	Claim 20; SEQ ID NO 56860; 103pp; English.
XX	
CC	The invention relates to isolated polynucleotide (I) and
CC	polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC	polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC	and gene mapping, and in recombinant production of (II). The
CC	polynucleotides are also used in diagnostics as expressed sequence tags
CC	for identifying expressed genes. (I) is useful in gene therapy techniques
CC	to restore normal activity of (II) or to treat disease states involving
CC	(II). (II) is useful for generating antibodies against it, detecting or
CC	quantitating a polypeptide in tissue, as molecular weight markers and as
CC	a food supplement. (II) and its binding partners are useful in medical
CC	imaging of sites expressing (II). (I) and (II) are useful for treating
CC	disorders involving aberrant protein expression or biological activity.

PR	22-AUG-2000	2000US-02266681
PR	22-AUG-2000	2000US-02266686
PR	22-AUG-2000	2000US-02271782
PR	23-AUG-2000	2000US-02287024
PR	30-AUG-2000	2000US-02282809
PR	01-SEP-2000	2000US-02292987
PR	01-SEP-2000	2000US-02299343
PR	01-SEP-2000	2000US-02299344
PR	01-SEP-2000	2000US-02299345
PR	05-SEP-2000	2000US-02299509
PR	05-SEP-2000	2000US-02304513
PR	06-SEP-2000	2000US-02304537
PR	06-SEP-2000	2000US-02304348
PR	08-SEP-2000	2000US-02310442
PR	08-SEP-2000	2000US-02313444
PR	08-SEP-2000	2000US-02313445
PR	08-SEP-2000	2000US-02314113
PR	08-SEP-2000	2000US-02314114
PR	08-SEP-2000	2000US-02320800
PR	08-SEP-2000	2000US-02320801
PR	12-SEP-2000	2000US-02318668
PR	14-SEP-2000	2000US-02323297
PR	14-SEP-2000	2000US-02323298
PR	14-SEP-2000	2000US-02323299
PR	14-SEP-2000	2000US-02324001
PR	14-SEP-2000	2000US-02324010
PR	14-SEP-2000	2000US-02330664
PR	14-SEP-2000	2000US-02330665
PR	14-SEP-2000	2000US-02330666
PR	14-SEP-2000	2000US-02330667
PR	21-SEP-2000	2000US-02344223
PR	21-SEP-2000	2000US-02344274
PR	25-SEP-2000	2000US-02343497
PR	25-SEP-2000	2000US-02343498
PR	25-SEP-2000	2000US-02343499
PR	26-SEP-2000	2000US-02354844
PR	27-SEP-2000	2000US-02358534
PR	27-SEP-2000	2000US-02358536
PR	29-SEP-2000	2000US-02365277
PR	29-SEP-2000	2000US-02365278
PR	29-SEP-2000	2000US-02365279
PR	29-SEP-2000	2000US-02365280
PR	29-SEP-2000	2000US-02365281
PR	29-SEP-2000	2000US-02365282
PR	29-SEP-2000	2000US-02365283
PR	29-SEP-2000	2000US-02365284
PR	29-SEP-2000	2000US-02365285
PR	29-SEP-2000	2000US-02365286
PR	29-SEP-2000	2000US-02365287
PR	29-SEP-2000	2000US-02365288
PR	29-SEP-2000	2000US-02365289
PR	29-SEP-2000	2000US-02365290
PR	29-SEP-2000	2000US-02365291
PR	29-SEP-2000	2000US-02365292
PR	29-SEP-2000	2000US-02365293
PR	29-SEP-2000	2000US-02365294
PR	29-SEP-2000	2000US-02365295
PR	29-SEP-2000	2000US-02365296
PR	29-SEP-2000	2000US-02365297
PR	29-SEP-2000	2000US-02365298
PR	29-SEP-2000	2000US-02365299
PR	29-SEP-2000	2000US-02365300
PR	29-SEP-2000	2000US-02365301
PR	29-SEP-2000	2000US-02365302
PR	29-SEP-2000	2000US-02365303
PR	29-SEP-2000	2000US-02365304
PR	29-SEP-2000	2000US-02365305
PR	29-SEP-2000	2000US-02365306
PR	29-SEP-2000	2000US-02365307
PR	29-SEP-2000	2000US-02365308
PR	29-SEP-2000	2000US-02365309
PR	29-SEP-2000	2000US-02365310
PR	29-SEP-2000	2000US-02365311
PR	29-SEP-2000	2000US-02365312
PR	29-SEP-2000	2000US-02365313
PR	29-SEP-2000	2000US-02365314
PR	29-SEP-2000	2000US-02365315
PR	29-SEP-2000	2000US-02365316
PR	29-SEP-2000	2000US-02365317
PR	29-SEP-2000	2000US-02365318
PR	29-SEP-2000	2000US-02365319
PR	29-SEP-2000	2000US-02365320
PR	29-SEP-2000	2000US-02365321
PR	29-SEP-2000	2000US-02365322
PR	29-SEP-2000	2000US-02365323
PR	29-SEP-2000	2000US-02365324
PR	29-SEP-2000	2000US-02365325
PR	29-SEP-2000	2000US-02365326
PR	29-SEP-2000	2000US-02365327
PR	29-SEP-2000	2000US-02365328
PR	29-SEP-2000	2000US-02365329
PR	29-SEP-2000	2000US-02365330
PR	29-SEP-2000	2000US-02365331
PR	29-SEP-2000	2000US-02365332
PR	29-SEP-2000	2000US-02365333
PR		





DT 18-FEB-2002 (first entry)  
XX Novel human diagnostic protein #29836.  
DE  
XX  
XX Human: chromosome mapping; gene mapping; gene therapy; forensic;  
KM food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX WO200175067-A2.  
XX  
XX  
PD 11-OCT-2001.  
XX  
XX 30-MAR-2001; 2001MO-US08631.  
XX  
XX 31-MAR-2000; 2000US-0540217.  
PR 23-AUG-2000; 2000US-0649167.  
XX  
XX (HYSE-) HYSEQ INC.  
PI Drmanac RT, Liu C, Tang YT,  
XX  
XX WPI; 2001-639362/73.  
DR N-PSDB; AAS94032.  
XX  
XX  
PT New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity  
PS Claim 20: SEQ ID No 60204; 103pp; English.  
XX  
XX The invention relates to isolated polynucleotide (I) and  
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,  
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
CC and gene mapping, and in recombinant production of (II). The  
CC polynucleotides are also used in diagnostics as expressed sequence tags  
CC for identifying expressed genes. (I) is useful in gene therapy techniques  
CC to restore normal activity of (II) or to treat disease states involving  
CC quantitating a polypeptide in tissue, as molecular weight markers and as  
CC a food supplement. (II) and its binding partners are useful in medical  
CC imaging of sites expressing (II). (I) and (II) are useful for treating  
CC disorders involving aberrant protein expression or biological activity.  
CC The polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. AAG0010-ABG30377 represent novel human  
CC diagnostic amino acid sequences of the invention.  
CC Note: The sequence data for this patent did not appear in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences.  
XX  
SQ Sequence 924 AA:  
  
Query Match 17.6%; Score 73.5; DB 22; Length 924;  
Best Local Similarity 33.7%; Pred. No. 5.3;  
Matches 29; Conservative 12; Mismatches 28; Indels 17; Gaps 6;  
  
OY 9 IYLFYFLSYSL--GDR---ARLCRLKTKKQOKKQ--ILNQ---SEVLFPSFTL----- 53  
DB 802 VILFHGSEWNLRLDQRLIFAKSWPRASRYOQGHODFLILSDLPVOVFIKDKLMERN 861  
OY 54 RKTGR--KGRWGGGGRGCTADTGG 77  
DB 862 RRTGRTKARIRWSDGQNGDLDWGG 887

AC AAM86657;  
XX  
DT 07-NOV-2001 (first entry)  
XX  
XX Human immune/haematopoietic antigen SEQ ID NO:14250.  
DE Human immune/haematopoietic; immune/haematopoietic antigen; cancer;  
XX cytostatic; gene therapy; vaccine; metastasis.  
KM  
XX Homo sapiens.  
XX  
XX WO200157182-A2.  
XX  
XX  
PD 09-AUG-2001.  
XX  
XX  
XX 17-JAN-2001; 2001MO-US01354.  
XX  
XX 31-JAN-2000; 2000US-0179065.  
PR 04-FEB-2000; 2000US-0180628.  
PR 24-FEB-2000; 2000US-0184664.  
PR 02-MAR-2000; 2000US-0186350.  
PR 16-MAR-2000; 2000US-0189874.  
PR 17-MAR-2000; 2000US-0190076.  
PR 18-APR-2000; 2000US-0198123.  
PR 19-MAY-2000; 2000US-0205515.  
PR 07-JUN-2000; 2000US-0209467.  
PR 28-JUN-2000; 2000US-0214886.  
PR 30-JUN-2000; 2000US-0215135.  
PR 07-JUL-2000; 2000US-0216647.  
PR 07-JUL-2000; 2000US-0216880.  
PR 11-JUL-2000; 2000US-0217487.  
PR 11-JUL-2000; 2000US-0217496.  
PR 14-JUL-2000; 2000US-0218290.  
PR 26-JUL-2000; 2000US-0220963.  
PR 26-JUL-2000; 2000US-0220964.  
PR 14-AUG-2000; 2000US-0224518.  
PR 14-AUG-2000; 2000US-0224519.  
PR 14-AUG-2000; 2000US-0225213.  
PR 14-AUG-2000; 2000US-0225214.  
PR 14-AUG-2000; 2000US-0225266.  
PR 14-AUG-2000; 2000US-0225267.  
PR 14-AUG-2000; 2000US-0225268.  
PR 14-AUG-2000; 2000US-0225270.  
PR 14-AUG-2000; 2000US-0225447.  
PR 14-AUG-2000; 2000US-0225757.  
PR 14-AUG-2000; 2000US-0225758.  
PR 14-AUG-2000; 2000US-0225759.  
PR 18-AUG-2000; 2000US-0226279.  
PR 22-AUG-2000; 2000US-0226681.  
PR 22-AUG-2000; 2000US-0226682.  
PR 22-AUG-2000; 2000US-0227182.  
PR 23-AUG-2000; 2000US-0227009.  
PR 30-AUG-2000; 2000US-0228924.  
PR 01-SEP-2000; 2000US-0229287.  
PR 01-SEP-2000; 2000US-0229343.  
PR 01-SEP-2000; 2000US-0229344.  
PR 01-SEP-2000; 2000US-0229345.  
PR 05-SEP-2000; 2000US-0229509.  
PR 05-SEP-2000; 2000US-0229513.  
PR 06-SEP-2000; 2000US-0230437.  
PR 06-SEP-2000; 2000US-0230438.  
PR 08-SEP-2000; 2000US-0231242.  
PR 08-SEP-2000; 2000US-0231243.  
PR 08-SEP-2000; 2000US-0231244.  
PR 08-SEP-2000; 2000US-0231413.  
PR 08-SEP-2000; 2000US-0231414.  
PR 08-SEP-2000; 2000US-0232080.  
PR 08-SEP-2000; 2000US-0232081.  
PR 12-SEP-2000; 2000US-0231968.  
PR 14-SEP-2000; 2000US-0232397.  
PR 14-SEP-2000; 2000US-0232398.  
PR 14-SEP-2000; 2000US-0232399.  
PR 14-SEP-2000; 2000US-0232400.

PR 14-SEP-2000; 2000US-0232401.  
 PR 14-SEP-2000; 2000US-0233063.  
 PR 14-SEP-2000; 2000US-0233064.  
 PR 14-SEP-2000; 2000US-0233065.  
 PR 21-SEP-2000; 2000US-0234223.  
 PR 21-SEP-2000; 2000US-0234274.  
 PR 25-SEP-2000; 2000US-0234997.  
 PR 25-SEP-2000; 2000US-0234998.  
 PR 26-SEP-2000; 2000US-0235484.  
 PR 27-SEP-2000; 2000US-0235834.  
 PR 27-SEP-2000; 2000US-0235836.  
 PR 29-SEP-2000; 2000US-0236327.  
 PR 29-SEP-2000; 2000US-0236367.  
 PR 29-SEP-2000; 2000US-0236368.  
 PR 29-SEP-2000; 2000US-0236369.  
 PR 29-SEP-2000; 2000US-0236370.  
 PR 02-OCT-2000; 2000US-0236802.  
 PR 02-OCT-2000; 2000US-0237037.  
 PR 02-OCT-2000; 2000US-0237038.  
 PR 02-OCT-2000; 2000US-0237039.  
 PR 13-OCT-2000; 2000US-0237040.  
 PR 13-OCT-2000; 2000US-0239935.  
 PR 13-OCT-2000; 2000US-0239937.  
 PR 20-OCT-2000; 2000US-0240960.  
 PR 20-OCT-2000; 2000US-0241221.  
 PR 20-OCT-2000; 2000US-0241785.  
 PR 20-OCT-2000; 2000US-0241786.  
 PR 20-OCT-2000; 2000US-0241787.  
 PR 20-OCT-2000; 2000US-0241808.  
 PR 20-OCT-2000; 2000US-0241809.  
 PR 01-NOV-2000; 2000US-0241826.  
 PR 01-NOV-2000; 2000US-0244617.  
 PR 08-NOV-2000; 2000US-0246474.  
 PR 08-NOV-2000; 2000US-0246475.  
 PR 08-NOV-2000; 2000US-0246476.  
 PR 08-NOV-2000; 2000US-0246477.  
 PR 08-NOV-2000; 2000US-0246478.  
 PR 08-NOV-2000; 2000US-0246523.  
 PR 08-NOV-2000; 2000US-0246524.  
 PR 08-NOV-2000; 2000US-0246525.  
 PR 08-NOV-2000; 2000US-0246526.  
 PR 08-NOV-2000; 2000US-0246527.  
 PR 08-NOV-2000; 2000US-0246528.  
 PR 08-NOV-2000; 2000US-0246532.  
 PR 08-NOV-2000; 2000US-0246609.  
 PR 08-NOV-2000; 2000US-0246610.  
 PR 08-NOV-2000; 2000US-0246611.  
 PR 08-NOV-2000; 2000US-0246613.  
 PR 17-NOV-2000; 2000US-0249207.  
 PR 17-NOV-2000; 2000US-0249208.  
 PR 17-NOV-2000; 2000US-0249209.  
 PR 17-NOV-2000; 2000US-0249210.  
 PR 17-NOV-2000; 2000US-0249211.  
 PR 17-NOV-2000; 2000US-0249212.  
 PR 17-NOV-2000; 2000US-0249213.  
 PR 17-NOV-2000; 2000US-0249214.  
 PR 17-NOV-2000; 2000US-0249215.  
 PR 17-NOV-2000; 2000US-0249216.  
 PR 17-NOV-2000; 2000US-0249217.  
 PR 17-NOV-2000; 2000US-0249218.  
 PR 17-NOV-2000; 2000US-0249244.  
 PR 17-NOV-2000; 2000US-0249245.  
 PR 17-NOV-2000; 2000US-0249264.  
 PR 17-NOV-2000; 2000US-0249265.  
 PR 17-NOV-2000; 2000US-0249297.  
 PR 17-NOV-2000; 2000US-0249299.  
 PR 17-NOV-2000; 2000US-0249300.  
 PR 01-DEC-2000; 2000US-0250160.  
 PR 01-DEC-2000; 2000US-0250391.  
 PR 05-DEC-2000; 2000US-0251030.  
 PR 05-DEC-2000; 2000US-0251988.  
 PR 05-DEC-2000; 2000US-0256719.  
 PR 06-DEC-2000; 2000US-0251479.

PR 08-DEC-2000; 2000US-0251856.  
 PR 08-DEC-2000; 2000US-0251868.  
 PR 08-DEC-2000; 2000US-0251869.  
 PR 08-DEC-2000; 2000US-0251989.  
 PR 08-DEC-2000; 2000US-0251990.  
 PR 11-DEC-2000; 2000US-0254097.  
 PR 05-JAN-2001; 2001US-0259678.  
 XX  
 PA (HUMAN) HUMAN GENOME SCI INC.  
 XX  
 PI Rosen CA, Barash SC, Ruben SM;  
 XX  
 DR WPI: 2001-483426/52.  
 DR N-PSDB; AAK59438.  
 XX  
 PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,  
 PT useful for preventing, diagnosing and/or treating cancers and  
 PT metastasis.  
 PS  
 PS Claim 11: SEQ ID NO 14250; 3071pp + Sequence Listing: English.  
 XX  
 CC AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)  
 CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic  
 CC activity, and can be used in gene therapy and vaccine production. (I)  
 CC proteins and polynucleotides may be used in the prevention, diagnosis and  
 CC treatment of diseases associated with inappropriate (I) expression. For  
 CC example, they may be used to treat disorders associated with decreased  
 CC expression by rectifying mutations or deletions in a patient's genome  
 CC that affect the activity of (I) by expressing inactive proteins or to  
 CC supplement the patients own production of (I). Additionally, (I)  
 CC polynucleotides may be used to produce the secreted (I), by inserting the  
 CC the nucleic acids into a host cell and culturing the cell to express the  
 CC protein. (I) proteins and polynucleotides may be used to prevent,  
 CC diagnose and treat immune/hematopoietic-related diseases, especially  
 CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703  
 CC to AAK87694 represent human immune/hematopoietic antigen genomic  
 CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169  
 CC represent sequences used in the exemplification of the present invention.  
 XX  
 SO Sequence 59 AA;  
 QY  
 Db 13 IYFLSYSLGDRARLCRKTKQKQKQEQIILKQSEVL 47  
 3 ITLLRSSLGNRRARLCLOKRRKKRRKKRRKARAL 37  
 RESULT 15  
 ID AAG84911 standard; Protein; 482 AA.  
 XX  
 AC AAG84911;  
 XX  
 DT 11-SEP-2001 (first entry)  
 XX  
 DE Shrimp white spot Bacilliform virus (WSBV) protein 2.  
 XX  
 XX Shrimp white spot Bacilliform virus; WSBV; diagnosis; viral infection;  
 KM antiviral agent; gene expression; antisense construct;  
 KW transgenic viral resistant shrimp.  
 XX  
 OS white spot syndrome virus.  
 OS  
 PN WO200138351-A2.  
 XX  
 PD 31-MAY-2001.  
 XX  
 PF 08-NOV-2000; 2000MO-US28888.  
 PF  
 XX 24-NOV-1999; 99CN-0124717.

```

XX (PENY-) PE CORP NY
PA (THIR-) THIRD INST OCEANOGRAPHY STATE OCEANI C A.
PA (SINO-) SINOGENOMAX CO LTD.
XX
XX
PI Xu X, Yang F, He J, Pham L, He M, Ye Y, Shen Y, Kodira C;
XX
DR WPI; 2001-355877/37.
DR N-PSDB; AAH62691.
XX
PT Primary nucleotide sequence of the shrimp white spot Bacilliform virus
PT (MSBV), useful for producing viral polypeptides that can be used to
PT screen for agents that are useful for treating MSBV infection -
XX
PS Claim 1; Figure 3; 626pp; English.
XX
CC The invention provides the primary nucleotide sequence of the MSBV genome
CC (AAH62689), predicted transcript sequences (AAH62689-AAH62839) and
CC encoded proteins (AAG84910-AAG85051) and oligonucleotide sequences
CC (AAH62840-63160) suitable for use as primers or probes. The nucleic acid
CC molecules and proteins of the invention are useful for diagnosis and
CC monitoring viral infection, in screens for antiviral agents and for
CC monitoring viral gene expression or activity during a treatment regimen.
CC The nucleic acid molecules are also useful as antisense constructs to
CC control viral gene expression in infected cells and tissues and to create
CC transgenic viral resistant shrimp.
XX
SQ Sequence 482 AA;

```

Query Match 17.5%; Score 73; DB 22; Length 482;  
 Best Local Similarity 27.0%; Pred. No. 3;  
 Matches 20; Conservative 19; Mismatches 35; Indels 0; Gaps 0;

```

OY 3 LSTHLPFLYLFYVLSLGDRLRLCLRKTKQOKEQIIRQSEVLFRRSETLRKTGKKRR 62
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 6 IATSLVLFPLFLVSIITLDGAKTIDOPFRKRKRKRRTSSEGDGIDGTGTNGGG 65
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
OY 63 WGGGGGGRGTADTG 76
   ||: || ||| |
DB 66 GGGEGGGGGTNGNG 79

```

Search completed: May 29, 2003, 15:18:12  
 Job time : 72 secs